PubMed Health⌕ Search

Biomedical subjects

Chrisoula D Scopa

Publications and source records attributed to Chrisoula D Scopa.

23 records · Page 2Linked to original sources
PubMed2003

Potential role of bcl-2 and ki-67 expression and apoptosis in colorectal carcinoma: a clinicopathologic study.

Colorectal cancer is associated with deregulation of apoptotic and proliferative processes. The purpose of this study was to investigate the presence of apoptosis and proliferation in colorectal cancer and evaluate their possible correlation with classic prognostic markers and patients' survival. Tumors from 117 patients, followed for 44-142 months, were studied immunohistochemically using the anti-bcl-2 and anti-Ki-67 antibodies. Apoptotic body index (ABI) was assessed by a standard TUNEL method. The bcl-2 protein was detected in 65% of adenocarcinomas with increased expression in low-grade and early-stage tumors. No association was noted between bcl-2 expression and proliferative activity, ABI, or patients' survival. A positive correlation was observed between ABI and proliferation (P < 0.05). Apoptosis was more frequently observed in advanced tumor stage or high-grade neoplasms. Cox analysis revealed that only tumor stage and grade constituted independent prognostic factors. The study suggests that there is a possible deregulation of the mechanisms that control bcl-2 expression in high-grade and advanced-stage colorectal carcinomas. Regulation of apoptosis is a complex phenomenon and other factors, including tumor heterogeneity, may be involved.

Adenocarcinoma↗
PubMed2002

S-100 protein+ dendritic cells and CD34+ dendritic interstitial cells in thyroid lesions.

Dendritic cells (DCs) are antigen-presenting cells and mature from precursor CD34+ stromal cells (dendritic interstitial cells [DICs]) or monocytes. The aim of the present study was to gain insight into the local immune response to various thyroid lesions. We investigated, immunohistochemically, the presence of S-100+ DCs and CD34+ DICs in 13 papillary carcinomas, 10 follicular carcinomas, 7 follicular adenomas, 1 Hurthle cell carcinoma, 1 Hurthle cell adenoma, 2 medullary carcinomas, 6 undifferentiated carcinomas, and 3 nodular goiters. Dense infiltrates of S-100+ DCs were noted in the majority of papillary carcinomas (mean: 66.4), while moderate infiltrates were observed in follicular adenomas (mean: 23.3), follicular carcinomas (mean: 23.5), and undifferentiated carcinomas (mean: 31.6). The remaining lesions showed slight infiltrates of scattered DCs. DICs were noted exclusively in neoplastic lesions, specifically at the periphery and within the tumor capsule. The increased number of DCs in papillary carcinomas is possibly correlated with their good prognosis. The specific distribution of DICs suggests a possible contribution to growth regulation of thyroid neoplasms.

Adenoma↗
PubMed2002

Immunohistochemical expression of TGF-beta1, p21WAF1, p53, Ki67, and angiogenesis in gastric carcinomas: a clinicopathologic study.

BACKGROUND: Transforming growth factors-beta (TGF-betas) are multifunctional polypeptides with crucial role as regulators of cellular growth and differentiation. It has been reported that TGF-beta1 plays a biphasic action on tumorigenesis thus inducing or inhibiting malignant properties of the epithelial cells. METHODS: TGF-beta1 expression was analyzed in 56 patients with gastric carcinoma by immunohistochemical methods and compared with the expression of p21, p53, and Ki67, as well as with angiogenesis. The correlation of these markers with clinicopathological parameters was also evaluated. RESULTS: TGF-beta1 expression was detected in 71% of tumors and was more frequent in adenocarcinomas of the intestinal type (p < 0.001). Positivity of p21WAF1, and p53 was observed in 32% and 51% of the tumors, respectively. A high Ki67 proliferating index was detected in 53.5% of the tumors. TGF-beta1 expression was significantly correlated with p21 expression (p < 0.001) and was inversely correlated with microvessel density. p21 expression was also higher in tumors with low proliferating index (p < 0.01). There was no apparent correlation between the expression of these markers and tumor stage, depth of invasion, or lymphnode metastases. CONCLUSION: The findings show that TGF-beta1 may be involved in the activation of the cdk inhibitor p21WAF1 in gastric adenocarcinomas, suggesting p53-independent induction of p21 in gastric cells. TGF-beta1 does not seem to contribute to the alteration of the angiogenic status of these tumors.

Adenocarcinoma↗
PubMedDate not supplied

Evaluation of margin status in lumpectomy specimens and residual breast carcinoma.

Residual disease leads to most local recurrences, especially in those patients treated with breast-conserving therapy (BCT). This study evaluates whether assessment of excisional biopsy margins accurately predicts the presence or absence of residual tumor in the lumpectomy bed. The margin status of 201 consecutive lumpectomy specimens of 178 infiltrating and 23 in situ breast carcinomas followed by reexcision were evaluated microscopically and classified as "positive" (tumor at the inked margins), "negative" (tumor more than 0.1 cm from the inked margins), "close" (tumor within 0.1 cm of the inked margins, but not transecting it), and "indeterminate" (biopsy not inked or fragmented). Tumor size and grade were also analyzed, as potential predictors for residual disease. Residual tumor was found in 41% of the patients: in 21% of the cases with negative margins, in 63% with positive margins, in 30% with close margins, and in 56% with indeterminate margins. In 37% of the positive and 70% of the close margin cases, no tumor was found in reexcised specimens. In 24% of the cases the residual disease was composed entirely of an in situ component of the same histologic type as the initial biopsy. No relationship was found between tumor size or grade and residual disease. For breast tumors, histologically negative and "close" biopsy margins do not guarantee complete excision. A number of factors seem to be responsible for the discrepancy between the margin status and the presence/absence of residual cancer in the lumpectomy bed.

Biopsy↗